RESPOND offers a research framework with a flexible organization, applying a common data model across different substudies, utilizing one shared data pool. Additionally, all involved in RESPOND can contribute to the ongoing scientific agendas. Together, these dynamic features facilitate responses to a broad range of unmet research needs.
The International Cohort Consortium of Infectious Disease (RESPOND) was formed in 2017 as a prospective, multi-cohort collaboration for the study of infectious diseases, with a special focus on people living with HIV. RESPOND was founded upon the groundwork laid by outstanding European HIV cohort collaborations such as EuroSIDA, the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) and Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) studies, and utilizes a similar, well-established infrastructure.
The large size of RESPOND consortium and a heterogeneous study population with participants from across the whole of Europe and Australia and a high degree of data quality ensure that the results are reliable and applicable to a broader population of people living with HIV. 17 cohorts are currently involved in the RESPOND consortium with over 30,000 individuals are under active follow up.
RESPOND aims to address clinically relevant research questions, including the risk and outcomes of non-AIDS comorbidities and the possible relationship to long-term ART exposure; to the outcomes and treatment of viral hepatitis B (HBV), hepatitis C (HCV), and tuberculosis (TB) co-infections; and to support public health initiatives.
|EATG contact person(s):||Alain Volny-Anne (member representing EATG)|
Giorgio Barbareschi – firstname.lastname@example.org
|Duration of the project/initiative:||2017 – ongoing|
|Initiative secretariat coordinator:||CHIP (Centre for Excellence for Health, Immunity and Infections)|
|Main partner(s):||AIDS Therapy Evaluation in the Netherlands Cohort (ATHENA); The Australian HIV Observational Database (AHOD); Austrian HIV Cohort Study (AHIVCOS); CHU Saint-Pierre (Belgium); EuroSIDA Cohort (Denmark); Frankfurt HIV Cohort Study (Germany); Georgian National AIDS Health Information System (AIDS HIS); Italian Cohort Naive Antiretrovirals (ICONA); Modena HIV Cohort (Italy); Nice HIV Cohort (France); PISCIS Cohort Study (Spain)|
|Main funding sources:||The International Cohort Consortium of Infectious Disease (RESPOND) has received funding from ViiV Healthcare LLC and Gilead Sciences. Additional support has been provided by participating cohorts contributing data in-kind and/or statistical support: Austrian HIV Cohort Study (AHIVCOS), The Australian HIV Observational Database (AHOD), CHU Saint-Pierre, University Hospital Cologne, EuroSIDA, Frankfurt HIV Cohort Study, Georgian National AIDS Health Information System (AIDS HIS), Modena HIV Cohort, San Raffaele Scientific Institute, Swiss HIV Cohort Study (SHCS), AIDS Therapy Evaluation in the Netherlands Cohort (ATHENA), Royal Free HIV Cohort Study.|
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.